CRISPR Therapeutics (NASDAQ: CRSP)
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor.
Is It Too Late to Buy CRISPR Therapeutics Stock?
The biotech has been making a lot of noise since late last year.
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
The biotech company keeps moving closer to bringing its promising first gene therapy to market.
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
This company's fortunes are likely to improve, and soon.
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time.
If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today
It would have been a great move.
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Breaking Down CRISPR Technology
What investors need to know.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.